Introduction
Cancer is a term used to describea disease in which abnormal cells divide in an uncontrolled fashion, and can invade other tissues [1,2]. Over the last century, lung cancer has become one of the biggest death-causing cancer of men worldwide and in some parts of the world also of women [3] . Twomajor types of lung cancer are known;small cell lung cancer (SCLC), which representsabout 10-15% of all lung cancers [4] ,and non-small cell lung cancer (NSCLC) which representsabout 85-90% of all lung cancers [5,6].
Although chemotherapy is considered one of the most effective approaches to treat cancer,it might kill,alongside the malignant cell, any normal cell thatgrows fast, which, in turn, may result in serious damage to patients [7] [8] [9] . Mostof the chemotherapeutic drugs work by impairing cell division by various mechanisms including damaging DNA and inhibition of the cellular machinery involved in cell division [10] .
HDACi's have demonstrated anticancer effects by selectively inducing apoptosis through modulating the expression of pro-apoptotic and anti-apoptotic genes [11] . Vorinostat is one of the inhibitors of HDAC family that shows to be efficacious and well-tolerated drug, thus,it has been considered a novel drug in the treatment of various cancers [12] .
Epigenetics as a term was first coined by Conrad Waddington in the early 1940s [13] . He defined epigenetics as "the branch of biology which studies the causal interactions between genes and their products which bring the phenotype into being." [14] . Collectively, epigenetics could be viewed as a major molecular mechanism that control gene expression without changing the underlying DNA sequence. The aim of the present investigation is to identify the role of Vorinostatcombined with other chemotherapeutic drugs (DNMTi) in controllingthe proliferation of lung cancer cells A549.
Harvesting the cells
After 96 h. of incubation, cells were removed from the incubator and the old medium was decanted. Cells were washed twice with warm PBS and trypsinized with 3 mL of 1X Trypsin EDTA (0.025%). Cells were then collected by centrifugation for 10 min. at 10,000 rpm.
Cell viability assay
According to Strober (2001) [25] ,the number of viable and non-viable cells were counted using Trypan blue exclusion test. Briefly, 50 µL of cell suspension was mixed with an equal volume of Trypan blue dye and left for 3 min. at room temperature.The mix was then loaded on a hemocytometer slide to be read usingan inverted microscope. Clear cells were considered viable, while blue ones were considered dead.
DNA extraction and DNA fragmentation assay
Genomic DNA was extracted from treated and untreated cells using Quick-DNA™ Miniprep Kit (Zymo Research, USA) following the kit's instructions. After extracting DNA, fragmentation assay was performed to assess the degradation pattern of DNA isolated from control and treated lung cancer cells. Briefly, 5µL of the eluted DNA was loaded on agarose gel (0.8%) and subjected to low voltage (15V) for 10 min. and then to 120V for 30 min.
Methylation quantification
Global methylation pattern was identified using MethylFlash DNA methylation kit (Epigentek, USA) following the kit's protocol.
Statistical analysis
Statisticalanalysis (ANOVA) for the obtained data was performed using SPSS 22.0.0.0 program that run under Windows [26] .In addition, the differences between means was calculated by using Duncan's MultipleRange test in the same program. Least Significant Difference (LSD) was also used to test the significance between all the treatments and control.
Results and Discussion
Cell viability Trypan blue test was performed to ensure the viability of the cultured cells. This test depends on dye exclusion as the live cells will not allow the dye to enter and, subsequently the live cells will appear clear when being examined under inverted microscope [27] . In this study, the initial cell count was 6x10 5 . The results obtained showed a significant decrease in the cell viability after being treated with different concentrations/combinations of the chemotherapeutics compared to control (Figure 1 . This wasin accordance with our data,although this conclusion may warrant further study.
In addition, ongoing studies are investigating the combination of Vorinostat with Temozolomide [33] . On the other hand, different drug combinations have resulted in different cell viability profiles indicating that even the lower concentrations were capable to induce cell death [29] . This reduction in the cell number might be attributed to the activation of the internal apoptotic machinery as indicated elsewhere Several researches indicated that chemotherapeutic treatment of cancer cell might induce DNA fragmentation, which will lead to apoptosis [37] [38] [39] [40] . DNAmethylation patterns are largely modified in cancer cells compared to control, and can therefore be used to distinguish cancer cells from normal tissues [41] . Results obtained ( Figure 3&4 ) showed a significant variation in the patterns of global methylation between different treatments.
Some drugs/combinations (Vorinostat combined with Procaine at concentration 3µM, Vorinostat combined with Temozolomide at the concentration of 5µM, Vorinostat at the concentration of 3µM, Vorinostat combined with Carboplatin at the concentration of 5µM, and Vorinostat combined with Cyclophosphamide at the concentration of 3µM) were able to globally hypomethylate the lung cancer cells A549. Genome-wide studies showed that reactivation of hypermethylated genes by combining more than one drug was significantly better than that induced by only one chemotherapeutic agent [42] .
Paper It was indicated earlier that histone and DNA methylation patterns in several malignant cells could be partially modified by the clinically promising HDAC inhibitor, Vorinostat [43] .Temozolomide shows its anti-cancer activity by methylating the DNA, as the interaction between DNA and Temozolomide causes localized distortion of DNA away from the normal B-form, resulting in a wider major groove and greater steric accessibility of functional groups in the base of the groove [44] . 
Conclusion
In the present study, the role of Vorinostat and other chemotherapeutic drugs (Carboplatin, Cyclophosphamide, Procaine, and Temozolomide) were evaluated as controller of the proliferation of lung cancer cells A549. Two final concentration of the drugs were applied (3µM and 5µM) to the cells, incubated for 96 hand cells viability were measured using the Trypan blue test. The global methylation pattern was assessed, and the results obtained indicated that different drug combinations were capable to hypo/hypermethylated the lung cancer cells A549. The present investigation needs more confirmatory studies to identify the actual mechanism(s) by which these drugs could control the malignant cells proliferation.
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